New developments in systemic therapy for hepatocellular carcinoma

RDF 

 
This item is provided by the institution :
Hellenic Society of Gastroenterology
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
New developments in systemic therapy for hepatocellular carcinoma (EN)

Dourakis, S.P.

Hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancers. ΗCC is the fifth most common malignancy and the third cause of cancer death globally (more than 500.000 cases yearly) with most deaths occurring within one year of diagnosis.1,2 In 90-95% οf cases, HCC is developed in cirrhotic liver. Liver transplantation (from cadaveric or living donors), surgical resection, percutaneous ethanol injection, transcatheter arterial chemoembolizatin (TACE) and radio-frequency (RF) thermal ablation microwaves achieve a relatively high response rate only in carefully selected candidates with small (diameter < 5 cm) tumors. Hepatic reserve often dictates the therapeutic options. Systemic therapy is appropriate for patients with advanced unresectable disease who are unsuitable for locoregional therapy and carry dismal prognosis. Nevertheless, up until now, there have been multitudes of negative systemic therapy trials for advanced HCC.3 So, in 60-75% οf HCC cases in Europe and the USA, no therapy short of palliative approaches was given to patients.4,5,6,7 (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2008-11-10


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 21, No 2 (2008); 83-87 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)